Alzamend Neuro (ALZN) Q1 2026 earnings summary

Executive summary

• Focused on developing novel therapeutics for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD, with two lead candidates (AL001 and ALZN002) in clinical development.

• No product revenue generated to date; operations funded primarily through equity and debt financings.

• Completed Phase IIA clinical trial for AL001 and initiated new brain imaging studies in partnership with Massachusetts General Hospital.

• ALZN002 Phase I/IIA trial ongoing, with a new CRO being sought after contract termination.

Financial highlights

• Net loss of $2.7 million for the quarter ended July 31, 2025, up 177% year-over-year.

• Operating expenses rose 181% to $2.7 million, driven by a significant increase in clinical trial fees.

• Cash balance of $5.6 million and working capital of $4.9 million as of July 31, 2025.

• Accumulated deficit reached $61.2 million; stockholders' equity at $5.3 million.

• No revenue recognized in the quarter.

Outlook and guidance

• Expects to continue incurring net losses and will require additional capital to fund ongoing and future clinical trials.

• Plans to advance AL001 and ALZN002 clinical programs and expand pipeline indications.

• Substantial doubt exists about the ability to continue as a going concern without new funding.